![Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients - ScienceDirect Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497121035837-gr1.jpg)
Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients - ScienceDirect
![Cancers | Free Full-Text | Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma Cancers | Free Full-Text | Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma](https://www.mdpi.com/cancers/cancers-15-04894/article_deploy/html/images/cancers-15-04894-g001.png)
Cancers | Free Full-Text | Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
![Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial - The Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial - The](https://www.thelancet.com/cms/attachment/fe60115b-e81f-4af1-8228-572eead9db60/gr2.jpg)
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial - The
![Daratumumab Alone or in Combination with Lenalidomide/Dexamethasone or Pomalidomide/Dexamethasone for Relapsed/Refractory MM | Research To Practice Daratumumab Alone or in Combination with Lenalidomide/Dexamethasone or Pomalidomide/Dexamethasone for Relapsed/Refractory MM | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2016/1/7/Slide1.jpg)
Daratumumab Alone or in Combination with Lenalidomide/Dexamethasone or Pomalidomide/Dexamethasone for Relapsed/Refractory MM | Research To Practice
![Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma | Advances in Therapy Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma | Advances in Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs12325-022-02226-x/MediaObjects/12325_2022_2226_Fig3_HTML.png)
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma | Advances in Therapy
![Cancers | Free Full-Text | Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma Cancers | Free Full-Text | Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma](https://pub.mdpi-res.com/cancers/cancers-15-04894/article_deploy/html/images/cancers-15-04894-g001-550.jpg?1696840178)
Cancers | Free Full-Text | Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
![Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/3f9a805c-3a94-4d62-8327-94885008b803/gr1.gif)
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology
![Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/4054c0bb-6add-4d79-a311-e460cd3357f2/gr1.gif)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
![Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma | Advances in Therapy Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma | Advances in Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs12325-022-02226-x/MediaObjects/12325_2022_2226_Fig1_HTML.png)
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma | Advances in Therapy
![Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial - The Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial - The](https://www.thelancet.com/cms/asset/d954cf17-118b-432b-92bc-417a5d90a2ce/gr1.jpg)
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial - The
![Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma | Advances in Therapy Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma | Advances in Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs12325-022-02226-x/MediaObjects/12325_2022_2226_Fig4_HTML.png)
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma | Advances in Therapy
![Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/6c0d27aa-ded1-4e96-b461-3eb5768b3f7f/gr2_lrg.jpg)
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology
![Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study - The Lancet Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study - The Lancet](https://www.thelancet.com/cms/attachment/db46a1da-7136-496e-9a73-5726d6f62ebf/gr1.gif)
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study - The Lancet
![Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment | Leukemia Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment | Leukemia](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41375-020-0813-1/MediaObjects/41375_2020_813_Fig1_HTML.png)
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment | Leukemia
![Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma - Transplantation ... Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma - Transplantation ...](https://www.astctjournal.org/cms/asset/62e2fae5-9499-44b4-9fec-c8cbf6624d4e/gr2.jpg)
Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma - Transplantation ...
![APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma](https://multiplemyelomahub.com/media/images/1a/97/picture2-apollo.png)
APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
![Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | Leukemia Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-020-01021-3/MediaObjects/41375_2020_1021_Fig1_HTML.png)
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | Leukemia
![APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma](https://multiplemyelomahub.com/media/images/88/ab/picture1-apollo.png)
APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
![Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/4326408a-095f-4765-ab3e-647bd5390344/gr1_lrg.gif)
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology
![Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma - Transplantation ... Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma - Transplantation ...](https://www.astctjournal.org/cms/attachment/aee245b9-718b-427d-8645-cd4c66fbcbeb/gr1.jpg)
Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma - Transplantation ...
![Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial - The Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial - The](https://www.thelancet.com/cms/attachment/768934c4-7db1-452e-90db-8c10bea1913b/gr1_lrg.jpg)